Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING
GLOBETECH PUBLISHING
JIB

Researchers Describe Novel Methods for Disabling Bacterial Proteases

By BiotechDaily International staff writers
Posted on 27 Feb 2014
Image: The target: bacterial protease ClpP (Photo courtesy of Technische Universitaet Muenchen).
Image: The target: bacterial protease ClpP (Photo courtesy of Technische Universitaet Muenchen).
Image: Several small molecules are able to split the protease ClpP into inactive smaller units, which massively disturbs the bacterial metabolism ClpP (Photo courtesy of Technische Universitaet Muenchen).
Image: Several small molecules are able to split the protease ClpP into inactive smaller units, which massively disturbs the bacterial metabolism ClpP (Photo courtesy of Technische Universitaet Muenchen).
A paper described previously unrecognized mechanisms that can be used to permanently deactivate critical bacteriological proteases.

Proteases are responsible for the pathogenic effects of many kinds of bacteria, and considerable research effort is involved in developing effective ways of inhibiting their action.

Investigators at the Technische Universitaet Muenchen (Munich, Germany) recently described novel approaches for silencing the activity of bacterial ClpP protease. In the January 29, 2014, issue of the Journal of the American Chemical Society they presented a novel mechanism of protease inhibition that relied on active-site-directed small molecules that disassembled the protease complex. They showed the applicability of this mechanism within the ClpP protease family, whose members are tetradecameric serine proteases and serve as regulators of several cellular processes, including homeostasis and virulence.

In addition, they reported the selective beta-sultam-induced dehydroalanine formation of the active site serine. This reaction proceeded through sulfonylation and subsequent elimination, thereby obliterating the catalytic charge relay system. The identity of the dehydroalanine was confirmed by mass spectrometry and crystallography. Activity-based protein profiling experiments suggested the formation of a dehydroalanine moiety in living Staphylococcus aureus cells upon beta-sultam treatment.

The mechanisms described here point towards the possibility of developing protease inhibitors that do not rely on complete blocking of the enzymes' catalytic or binding sites.

“ClpP inhibitors used in the past have one decisive disadvantage,” said senior author Dr. Stephan Sieber, professor of organic chemistry at the Technische Universitaet Muenchen. “They do not permanently disarm the proteins, but only work for a few hours. On top of that, to be effective they must attack all active centers of the protein.”

Related Links:

Technische Universitaet Muenchen



comments powered by Disqus

Channels

Drug Discovery

view channel

Ibuprofen May Restore Immune Function in Older Individuals

New research suggests that macrophages from the lungs of old mice respond differently to infections than those of young mice, and ibuprofen given to the mice reversed these changes. New research using lab mice suggests that the solution to more youthful immune function might already be a common over-the-counter pain reliever.... Read more

Therapeutics

view channel
Image: Hair follicle (blue) being attacked by T cells (green) (Photo courtesy of Christiano Lab/Columbia University Medical Center).

Hair Restoration Method Clones Patients’ Cells to Grow New Hair Follicles

Researchers have developed of a new hair restoration approach that uses a patient’s cells to grow new hair follicles. In addition, the [US] Food and Drugs Administration (FDA) recently approved a new drug... Read more

Lab Technologies

view channel
Image: Leica Microsystems launches the inverted research microscope platform Leica DMi8 (Photo courtesy of Leica Microsystems).

New Inverted Microscope Designed to Readily Adapt to Changing Research Demands

A new inverted microscope for biotech and other life science laboratories was designed to readily accommodate modifications and upgrades to allow it to keep current with changing research demands and interests.... Read more

Business

view channel

Partnership Established to Decode Bowel Disease

23andMe (Mountain View, CA,USA), a personal genetics company, is collaborating with Pfizer, Inc. (New York, NY, USA), in which the companies will seek to enroll 10,000 people with inflammatory bowel disease (IBD) in a research project designed to explore the genetic factors associated with the onset, progression, severity,... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.